Bioavailability, food effect and tolerability of S-naproxen betainate sodium salt monohydrate in steady state

Arzneimittel-Forschung/Drug Research

Volumn 48, Issue 9, 1998, Pages 935-940

  Marzo, Antonio ^a   Dal Bo, Lorenzo ^a   Wool, Corinne ^b   Cerutti, Renata ^b  

^a Inst Pharmacokinetic Analyt S   (Switzerland)

^b Bracco SpA   (Italy)

Author keywords

Anti inflammatories, non steroidal; Aprenin , bioavailability, clinical studies, tolerability; CAS 22204 53 1; Naproxen betainate sodium salt monohydrate

Indexed keywords

APRENIN; NAPROXEN; NAPROXEN BETAINATE SODIUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG TOLERABILITY; ENANTIOMER; EPIGASTRIC PAIN; FEMALE; FLATULENCE; FLUOROMETRY; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; MICROCAPSULE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; STEADY STATE; TECHNIQUE;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIETARY FATS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; NAPROXEN; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, FLUORESCENCE;

EID: 0031720913     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Adams, S. S., Bresloff, P., Mason, C. G., J. Pharm. Pharmacol. 28, 256 (1976)
2. Caldwell, J., Hutt, A. J., Fournel-Gigleux, S., Biochem. Pharmacol. 37, 105 (1988)
3. Marzo, A., Arzneim.-Forsch./Drug Res. 44 (I), 791 (1994)
4. Sevelius, H., Runkel, R., Segre, E. et al., Br. J. Clin. Pharmacol. 10, 259 (1980)
5. Gamst, O. N., Vesje, A. K., Aarbakke, J., Int. J. Clin. Pharmacol. Ther. Toxicol. 22, 99 (1984)
6. Kelly, J. G., Kinney, C. D., Devane, J. G. et al., Eur. J. Clin. Pharmacol. 36, 383 (1989)
7. Brogden, R. N., Heel, R. C., Pakes, G. E. et al., Drugs 20, 24 (1980)
8. Marzo, A., Ripamonti, M., Benatti, P. et al., Arzneim.-Forsch./Drug Res. 47 (I), 381 (1997)
9. Marzo, A., Monti, N., Ripamonti, M. et al., Arzneim.-Forsch./Drug Res. 47 (I), 385 (1997)
10. Note for guidance: Investigation of bioavailability and bioequivalence. CPMP Working party on efficacy of medicinal products. III/54/89-EN FINAL, December 1991
11. Marzo, A., Balant, L.P., Arzneim.-Forsch. 45 (I), 109 (1995)
12. In vivo Bioequivalence Guidances/General Information, United States Pharmacopoeia 23, 1929 (1995)
13. Marzo, A., J. Pharm. Pharmacol. 49, 1259 (1997)
14. Marzo, A., Pharmacol. Res. 36, 425 (1997)
15. Davies, N. M., Anderson. K. E., Clin. Pharmacokinet. 32, 268 (1997)
16. Mroszczak, E., Yee, J. P., Bynum, L., J. Clin. Pharmacol. 28, 1128 (1988)
17. Palazzini, E., Cristofori, M., Babbini, M., Int. J. Clin. Pharm. Res. 12, 179 (1992)
18. Rao, B. R., Rambhau, D., Rao, V. V. S., Chronobiol. Int. 10, 137 (1993)
19. Calvo, M. V., Dominguez-Gil, A., Int. J. Pharm. 16, 215 (1983)
20. Upton, R. A., Williams, R. L., Kelly, J. et al., Br. J. Clin. Pharmacol. 18, 207 (1984)
21. Van Den Ouweland, F. A., Franssen, M. J. A. M., Van De Putte, L. B. A. et al., Br. J. Clin. Pharmacol. 23, 189 (1987)
22. Van Den Ouweland, F. A., Gribnau, F. W. J., Tan, Y. et al., Clin. Pharmacokinet. 11, 511 (1986)
23. Wilkinson, P., Jeremy, R., Brooks, F. P. et al., Ann. Int. Med. 63, 109 (1965)
24. Antilla, M., Haataja, M., Kasanen, A., Eur. J. Clin. Pharmacol. 18, 263 (1980)